Quince Therapeutics (QNCX) Capital Expenditures (2018 - 2025)
Quince Therapeutics (QNCX) posted quarterly Capital Expenditures of $4000.0 for Q4 2025, down 96.99% year-over-year from $133000.0 in Q4 2024, and down 94.59% quarter-over-quarter from $74000.0 in Q3 2025.
Quince Therapeutics (QNCX) Capital Expenditures (2018 - 2025) Analysis & Trends
Quince Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $4000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures fell 96.99% year-over-year to $4000.0; the TTM figure through Mar 2026 stood at $204000.0 (down 44.26% YoY), while the FY2025 annual figure was $352000.0, up 36.96% from the prior year.
- Capital Expenditures for Q4 2025 stood at $4000.0, down from $74000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $148000.0 in Q1 2025, with the low at $4000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $48000.0 (2022), against an average of $67625.0.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures soared 2620.0% in 2023, then sank 96.99% in 2025.
- Quince Therapeutics' Capital Expenditures stood at $44000.0 in 2021, then soared by 77.27% to $78000.0 in 2022, then tumbled by 69.23% to $24000.0 in 2023, then soared by 454.17% to $133000.0 in 2024, then tumbled by 96.99% to $4000.0 in 2025.
- Business Quant data shows QNCX's Capital Expenditures at $4000.0 in Q4 2025, $74000.0 in Q3 2025, and $126000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,000.00 |
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 126,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Mar 31, 2025 | 148,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 39,000.00 |
| Jun 30, 2024 | 39,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Mar 31, 2024 | 39,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Mar 31, 2023 | 136,000.00 |
| Mar 31, 2023 | 136,000.00 |